Viking Therapeutics, Inc.
VKTX evidence brief
What we can confirm
- BioSniper Score:
- 5.2 / 10
- Market Cap:
- $3.93B
- Lead Asset:
- VK2735 (Phase 1)
What it means
What to watch
Prepared research question
What matters most for VKTX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · VKTX
Viking Therapeutics, Inc. (VKTX) is a clinical-stage biopharmaceutical company developing novel therapies for metabolic and endocrine disorders, with its lead candidate VK2735, a dual GLP-1/GIP receptor agonist, in Phase 3 trials for weight management.
Key risk: No revenue, ongoing losses
BioSniper Score
Based on 5 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate · 7 clinical trials · 2 catalysts for Viking Therapeutics, Inc..
Viking Therapeutics, Inc. (VKTX) is a clinical-stage biopharmaceutical company developing novel therapies for metabolic and endocrine disorders, with its lead candidate VK2735, a dual GLP-1/GIP receptor agonist, in Phase 3 trials for weight management.
- Cash & equivalents of $125.8M as of 2026-06-30 [sec].
- Lead drug candidate VK2735 (dual GLP-1/GIP agonist) is in Phase 3 for weight management in obese adults with type 2 diabetes [catalyst].
- Initiated Phase 1 trial of VK3019, a dual amylin and calcitonin receptor agonist for weight loss, with data expected in 3Q26 [news · published 2026-06-24].
- Net income of -$128.0M for the six months ended June 30, 2026 [sec].
- Shareholders' equity of $408.3M as of 2026-06-30 [sec].
What works
- Strong cash position of $125.8M as of 2026-06-30 provides runway for ongoing clinical development [sec].
- VK2735 has advanced to Phase 3, indicating confidence in its clinical profile and potential in the obesity market [catalyst].
- Diversified pipeline includes VK3019 (amylin/calcitonin agonist) entering Phase 1, expanding beyond GLP-1/GIP mechanisms [news · published 2026-06-24].
- Company believes it has sufficient capital to fund operations for at least the next 12 months as of July 2026 [sec_mda · as of 2026-07-29].
What to weigh
- No revenue generated to date; net loss of $128.0M for the six months ended June 30, 2026 [sec].
- VK2735 faces intense competition from at least 7 other obesity drug developers, including Novo Nordisk and Boehringer Ingelheim [pipeline].
- Company acknowledges it will need to raise additional capital and that funding may not be available on acceptable terms [sec_mda · as of 2026-04-30].
- Differentiation of VK2735 versus established drugs like Zepbound is described as limited [news · published 2026-09-17].
From the filings
Quoted directly from source documents.
VK2735 Phase 3 trial initiation for weight management in type 2 diabetes
“A Phase 3 Randomized, Double-Blind, Placebo-Controlled, 78-Week Efficacy and Safety Study of VK2735 Administered Subcutaneously for Weight Management in Participants With Type 2 Diabetes Who Are Obese, or Overweight”
Catalysts · June 23, 2025
VK3019 Phase 1 trial initiation and data timeline
“Viking Therapeutics Initiates Phase 1 Ascending Dose Trial Of VK3019, An Investigational Dual Amylin And Calcitonin Receptor Agonist For Weight Loss; Data Expected In 3Q26”
News · June 24, 2026
Need for additional capital
“We will need to raise additional capital to fund our operations and complete our ongoing and planned clinical trials.”
SEC MD&A · April 30, 2026
Catalyst timeline
- 2025-06-23 · Phase 3 start of VK2735 for weight management in type 2 diabetes — A 78-week study evaluating subcutaneous VK2735 in obese/overweight participants with type 2 diabetes.
- 2025-11-18 · Phase 1 start of VK2735 oral tablet in obese adults without comorbidities — Evaluates safety, tolerability, PK, and PD of oral VK2735.
- 2026-07-06 · Phase 1 start of VK3019 (amylin/calcitonin agonist) single ascending dose study — First-in-human study of a novel dual agonist for weight loss.
Risks & what to watch (4)›
Key risks
- No revenue, ongoing losses — Zero revenue and net loss of $128.0M in H1 2026; losses expected to increase [sec].
- Intense obesity drug competition — VK2735 competes with 7+ other programs including Novo Nordisk and Boehringer Ingelheim [pipeline].
- Capital need for development — Company must raise additional capital; funding may not be available on acceptable terms [sec_mda · as of 2026-04-30].
- Limited differentiation from peers — VK2735 differentiation vs Zepbound is described as limited [news · published 2026-09-17].
What to watch
- Phase 3 data for VK2735 in weight management, which could determine competitive positioning [catalyst].
- Phase 1 data for VK3019 expected in 3Q26, providing early read on a novel mechanism [news · published 2026-06-24].
- Cash runway updates and any new financing activities, given the need for additional capital [sec_mda · as of 2026-04-30].
- Maintenance data for VK2735, which may clarify differentiation from existing GLP-1/GIP drugs [news · published 2026-09-17].
Sources: Catalysts · News · Pipeline · SEC MD&A · Generated October 12, 2026 · How we verify sources →
Run Viking Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Viking Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.28 · 0% dilution
Lead: Phase 1
1 candidate
2 upcoming, next in ~1d
0 buys · 3 sells (180d)
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
408
Total value held
$2.41B
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 6,880,290 | $223.9M |
| fmr llc | 6,024,753 | $196.0M |
| vanguard capital management llc | 5,012,502 | $163.1M |
| vanguard portfolio management llc | 4,464,298 | $145.3M |
| two sigma investments, lp | 4,432,142 | $144.2M |
| state street corp | 4,395,557 | $143.0M |
| raymond james financial inc | 2,075,403 | $113.5M |
| morgan stanley | 3,013,928 | $98.1M |
| geode capital management, llc | 2,082,067 | $67.8M |
| american century companies inc | 2,078,577 | $67.6M |
Showing top 10 of 408 institutional holders of Viking Therapeutics, Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 19, 2026- % of float
- 21.9%
- Days to cover
- 9.7
- Shares short
- 24,006,215
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
VKTX short interestGovernance
Frequently asked questions
What is the AI investment thesis for Viking Therapeutics, Inc.?
Viking Therapeutics, Inc. (VKTX) is a clinical-stage biopharmaceutical company developing novel therapies for metabolic and endocrine disorders, with its lead candidate VK2735, a dual GLP-1/GIP receptor agonist, in Phase 3 trials for weight management.
What is Viking Therapeutics, Inc.'s lead drug candidate?
Viking Therapeutics, Inc.'s most advanced tracked candidate is VK2735 (Phase 1) for Weight Loss; Obese Adults.
What is Viking Therapeutics, Inc.'s next catalyst?
Viking Therapeutics, Inc.'s next tracked catalyst is a Phase3_Start event — "Phase3_Start: A Phase 3 Randomized, Double-Blind, Placebo-Controlled, 68-Week Efficacy and Safety Study of VK2735 Administered Orally for Weight Management in Participants Without Type 2 Diabetes Mellitus Who Are Obese, or Overweight With at Least One Weight-related Comorbid Condition" — expected October 15, 2026.
Who is the CEO of Viking Therapeutics, Inc.?
Dr. Brian Lian Ph.D. is the chief executive officer of Viking Therapeutics, Inc. (VKTX).
Where is Viking Therapeutics, Inc. headquartered?
Viking Therapeutics, Inc. (VKTX) is headquartered in San Diego, CA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.